Pharmagro At CPHI 2025
It was great to be at CPHI 2025 in Frankfurt meeting existing and potential clients. We contacted around 100 companies, received great feedback and enjoyed the Messe.
Thank you to HIPRA a newly launched CDMO. Like us they set up this year and have up to date facilities in Girona.
- Drug discovery capabilities, including viral and bacterial antigens for vaccine development, recombinant proteins (such as mAbs), peptides, enzymes, and more
- Cell line and strain development tailored for both cell culture (mammalian, avian, or insect) and microbial (bacterial and yeast)
- Accelerated cell line development pipeline “from gene to manufacturing scale” for the production of recombinant proteins and monoclonal antibodies
- Stability studies and final buffer composition development are conducted to assess, ensure, and extend the longevity and reliability of biological products
More insight into CPHI in the following posts!
